publicações selecionadas
-
artigo académico
- New Ruthenium-Cyclopentadienyl Complexes Affect Colorectal Cancer Hallmarks Showing High Therapeutic Potential. Pharmaceutics. 2023
- Ruthenium(II)-Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs. Pharmaceutics. 2022
- Biotinylated Polymer-Ruthenium Conjugates: In Vitro and In Vivo Studies in a Triple-Negative Breast Cancer Model. Pharmaceutics. 2022
- Vulvovaginal candidiasis and asymptomatic vaginal colonization in Portugal: Epidemiology, risk factors and antifungal pattern. Blood. 2022
- A New Family of Iron(II)-Cyclopentadienyl Compounds Shows Strong Activity Against Colorectal and Triple Negative Breast Cancer Cells.. Molecules (Basel, Switzerland). 2020
- Ruthenium–Cyclopentadienyl Bipyridine–Biotin Based Compounds: Synthesis and Biological Effect. Inorganic Chemistry. 2019
- Polymer “ruthenium-cyclopentadienyl” conjugates - New emerging anti-cancer drugs. European Journal of Medicinal Chemistry. 2019
- Novel ruthenium methylcyclopentadienyl complex bearing a bipyridine perfluorinated ligand shows strong activity towards colorectal cancer cells. European Journal of Medicinal Chemistry. 2018
-
documento
- Fighting pancreatic cancer: PMC79 the new ruthenium agent targeting KRAS mutations 2025
- New ruthenium-cyclopentadienyl agents as a new strategy to fight colorectal cancer 2021
- Ruthenium-based agents as promising metallodrugs to fight colorectal cancer 2020
- A New family of Iron-Cyclopentadienyl compounds: Synthesis and Biological Evaluation 2020
- Fighting colorectal cancer with ruthenium-based agents 2020
- Multifunctional polymer-ruthenium conjugates: promising therapeutic approach to colorectal cancer 2018